Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes: Selective norepinephrine reuptake inhibitor (NRI) with 5HT1A partial agonism & duration : Daily dosing or N/A (replacement)

Use the filters below to narrow your results.

generic:
None (1)
brand:
Qelbree (1)
classes: (Click arrow to add another value)
mechanism:
Selective NET inhibitor (no significant DAT activity, distinguishes from amphetamine/methylphenidate). Also: 5HT1A receptor partial agonism, 5HT2B and 5HT7 receptor antagonism. The serotonergic actions may underlie better tolerability and possibly different efficacy spectrum than atomoxetine. (1)
uses:
ADHD in children (6+), adolescents, and adults (FDA-approved 2021 for pediatric, 2022 for adult) (1)
starting dose:
Pediatric 6-11: 100 mg PO daily, titrate weekly to max 400 mg. Adolescent 12-17: 200 mg, max 400 mg. Adult: 200 mg, max 600 mg. (1)
preparations:
100 mg, 150 mg, 200 mg extended-release capsules (can be sprinkled on food) (1)
fda max:
400 mg/d (pediatric); 600 mg/d (adult) (1)
routes:
Oral (1)
onset:
ADHD symptom improvement reported within 1-2 weeks (faster than atomoxetine which takes 4-6 weeks) (1)
duration: (Click arrow to add another value)
halflife:
~7 hours (1)
bioavailability:
Adequate oral bioavailability with extended-release formulation (1)
pregnancy:
Limited data (1)
legal:
Rx, '''not a controlled substance''' (no DEA scheduling) (1)

Showing below up to 1 result in range #1 to #1.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"